Shorter Ocrelizumab Infusion Time for Multiple Sclerosis Does Not Affect Safety Profile

No notable difference in reactions with two-hour infusion in ENSEMBLE PLUS substudy

intravenous infusion line

Reducing the infusion time of ocrelizumab to just two hours for the treatment of early relapsing-remitting multiple sclerosis (RRMS) leads to similar frequency and severity of infusion-related reactions as infusing over the conventional duration of 3.5 hours. That’s the conclusion of investigators with the completed ENSEMBLE PLUS substudy as reported by Robert Bermel, MD, Director of Cleveland Clinic’s Mellen Center for Multiple Sclerosis Treatment and Research, in a poster presentation at the American Academy of Neurology 2023 annual meeting.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“Reducing infusion time offers benefits both to patients and to infusion staff,” says Dr. Bermel, who is on steering committees for the ENSEMBLE and ENSEMBLE PLUS multicenter trials. “As a result of these findings, we have made the shorter infusion schedule our default at Cleveland Clinic.”

He adds that the final results from ENSEMBLE PLUS are expected to be published shortly.

ENSEMBLE in brief

ENSEMBLE (NCT03085810) is an ongoing prospective, multicenter, single-arm, phase 3b study designed to evaluate the effectiveness and safety of ocrelizumab in early RRMS. The open-label treatment period will last 192 weeks, with at least 48 weeks of follow-up. The trial enrolled 1,239 patients and is expected to be completed in August 2024.

Ocrelizumab, a second-generation recombinant humanized monoclonal that targets B cells, was approved for the treatment of primary progressive and relapsing MS in 2017.

The drug is administered intravenously as two 300-mg infusions on days 1 and 15, followed by one 600-mg infusion dose administered over about 3.5 hours (the conventional infusion time) every 24 weeks for a maximum of eight doses.


ENSEMBLE PLUS substudy design

The optional substudy reported here — ENSEMBLE PLUS — used a randomized, double-blind design to evaluate the safety of shorter versus conventional infusion of ocrelizumab.

After the first two 300-mg infusions, 745 patients were randomized to receive the remaining doses of 600 mg infused either at the conventional rate or a reduced rate (about two hours, followed by saline infusion over the remaining 1.5 hours to mimic the conventional infusion).

The conventional group (N = 373) and the reduced infusion group (N = 372) were similar in age, sex, weight, body mass index and time since first MS symptoms.

Substudy results of infusion reactions

Primary analyses of the ENSEMBLE PLUS results were previously published in Multiple Sclerosis and Related Disorders (2020;46:102492) and in Neurology: Neuroimmunology & Neuroinflammation (2020;7[5]:e807). They indicated that conventional and shorter ocrelizumab infusion periods had similar frequency, severity and symptoms of infusion-related reactions.

The current report highlights the following results:

  • In both arms, most infusion-related reactionswere mild to moderatein severity, and none were life-threatening or fatal.
  • The most frequent infusion-related reactions during the first dose were throat irritation (occurring in 5.1% of the conventional group vs. 8.6% in the reduced infusion group)and dysphagia (1.9% vs. 2.2%, respectively).
  • The most common symptoms occurring 24 hours post-infusion following the first dose were fatigue (6.2% conventional vs. 5.4% reduced) and headache (7.0% vs. 5.1%, respectively).
  • The frequency of infusion-related reactions that led to an intervention was 10.5% in the conventional group and 14.8% in the reduced group. These reactions led to either slowed or interrupted infusion, but not discontinuance.

Dr. Bermel also emphasized the following overall trends:

  • The frequency of infusion-related reactions decreased with subsequent doses.
  • Previous infusion-related reactions — particularly throat irritation — were a risk factor for subsequent reactions but were not influenced by infusion time.
  • A medical history of headaches or migraines did notcorrelate with these symptoms following infusion.

Most patients prefer shorter infusion

This was the first report to provide evidence of patient preference for the shorter infusion strategy. Following unblinding of the ENSEMBLE PLUS substudy, patients could choose to switch their infusion regimen. The vast majority chose to either remain with the shorter infusion group or change to it. After the choices were made, just 90 patients were undergoing treatment with the conventional infusion time versus 610 with the reduced infusion time.

Dr. Bermel notes that Cleveland Clinic now routinely infuses ocrelizumab over two hours, regardless of MS stage. The study results led to an FDA-approved label change for ocrelizumab, allowing for the two-hour infusion time for patients who have not had a previous serious infusion reaction with the drug.

“Patients who have had a previous infusion-related reaction should receive infusions in a hospital-based infusion center so they can be monitored more carefully,” Dr. Bermel emphasizes. “They should not use stand-alone infusion centers without physician supervision on the premises.”

Related Articles

neuron affected by neuromyelitis optica
Novel Monoclonal Antibodies for NMOSD Show Strong Efficacy and Safety in Real-World Study

Early experience with the agents confirms findings from clinical trials

histology image of a gray matter lesion in a multiple sclerosis brain
Study Suggests Protective Role for Microglia at Borders of Gray Matter Lesions in Progressive MS

Findings challenge dogma that microglia are exclusively destructive regardless of location in brain

illustration of a neuron affected by multiple sclerosis
Clinical Trials in Progressive MS: An Assessment of Advances and Remaining Challenges

New review distills insights from studies over the past decade

photo of doctor performing neurologic exam on a patient
A New Guide to the Differential Diagnosis of Multiple Sclerosis

Updated consensus approach helps clinicians efficiently improve diagnostic accuracy

Reproductive Issues and Multiple Sclerosis: 20 Frequently Asked Questions

The disease is not a barrier to pregnancy, but risks from disease-modifying therapies must be managed

23-NEU-3813861 multiple-sclerosis-patient_650x450
How the SPRINT-MS Follow-On Study Aims to Enhance Future Trials of Progressive Multiple Sclerosis

In search of optimal imaging biomarkers, best methods for long-term follow-up

23-NEU-3991918 CQD hero_650x450
For Older Patients With Multiple Sclerosis, Discontinuing Disease-Modifying Therapy May Be an Option

Risk of new MS activity is small in those older than 55 with stable disease who stop MS therapy

DELIVER-MS Trial Extended to Guide Philosophy for Long-Term Multiple Sclerosis Therapy

$1.1M award expands follow-up to six years with focus on clinical endpoints